Morepen Laboratories reports net sales revenue of Rs 196.60 crore in Q2’FY 2019-20
The company's pharma division commenced commercial sales of its probiotics in India during Q1 FY 2019-20 and has made steady…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Sushil Suri
Morepen Labs adds three new drugs to its API Portfolio
The three bulk drugs/APIs are Rivaroxaban, Vildagliptin and UDCA will augment Morepen’s presence in the cardiac and diabetic…
Morepen Labs’ Net Profit rises by 256 per cent led by higher APIs exports
The company’s net sales revenue (standalone) in Q1 ’FY 2019-20 stood at Rs 186.70 crore showing a growth of 25.4 per cent…